Nonalcoholic fatty liver disease: Definitions, risk factors, and workup
- PMID: 31186860
- PMCID: PMC6499283
- DOI: 10.1002/cld.81
Nonalcoholic fatty liver disease: Definitions, risk factors, and workup
Figures



Similar articles
-
Nonalcoholic fatty liver disease.Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):57-62. doi: 10.1007/s11894-999-0088-1. Curr Gastroenterol Rep. 1999. PMID: 10980928 Review.
-
Pathological Connections between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease.Kidney Dis (Basel). 2022 Oct 31;8(6):458-465. doi: 10.1159/000527834. eCollection 2022 Dec. Kidney Dis (Basel). 2022. PMID: 36590682 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk.Adv Kidney Dis Health. 2023 Jul;30(4):315-335. doi: 10.1053/j.akdh.2023.04.001. Adv Kidney Dis Health. 2023. PMID: 37657879 Review.
-
Fatty liver and the metabolic syndrome.Curr Opin Gastroenterol. 2007 Mar;23(2):193-8. doi: 10.1097/MOG.0b013e32801421a9. Curr Opin Gastroenterol. 2007. PMID: 17268250 Review.
-
Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.SAGE Open Med. 2020 Jun 20;8:2050312120933804. doi: 10.1177/2050312120933804. eCollection 2020. SAGE Open Med. 2020. PMID: 32612827 Free PMC article. Review.
Cited by
-
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.Front Cell Dev Biol. 2024 Sep 11;12:1423936. doi: 10.3389/fcell.2024.1423936. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39324073 Free PMC article.
-
The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease.Endocrinol Diabetes Metab. 2020 Apr 5;3(4):e00127. doi: 10.1002/edm2.127. eCollection 2020 Oct. Endocrinol Diabetes Metab. 2020. PMID: 33102796 Free PMC article. Review.
-
Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?World J Diabetes. 2021 Sep 15;12(9):1479-1493. doi: 10.4239/wjd.v12.i9.1479. World J Diabetes. 2021. PMID: 34630901 Free PMC article. Review.
-
NLRP3 Inflammasome in Acute and Chronic Liver Diseases.Int J Mol Sci. 2024 Apr 20;25(8):4537. doi: 10.3390/ijms25084537. Int J Mol Sci. 2024. PMID: 38674122 Free PMC article. Review.
-
Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.Front Pharmacol. 2022 Apr 4;13:841132. doi: 10.3389/fphar.2022.841132. eCollection 2022. Front Pharmacol. 2022. PMID: 35450049 Free PMC article.
References
-
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592‐1609. - PubMed
-
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413‐1419. - PubMed
-
- Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander‐Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467‐2474. - PubMed
-
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313‐1321. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources